MIRA Pharmaceuticals, Inc. (MIRA) stock
MIRANasdaqPharmaceutical Preparations
$0.59−0.05 (-7.66%)
Close on Nov 18, 2026Market cap $24.84MP/E –Yield –
MIRA Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
MIRA Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $2.14M, down 21.9% year over year. For fiscal 2025 it was $1.72M, down 48.0% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.72M | -48.0% |
| FY2024 | Dec 31, 2024 | $3.31M | +110.1% |
| FY2023 | Dec 31, 2023 | $1.57M | -33.1% |
| FY2022 | Dec 31, 2022 | $2.35M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $705.79K | +42.2% |
| Q1 FY2026 | Mar 31, 2026 | $524.78K | +66.9% |
| Q4 FY2025 | Dec 31, 2025 | $496.54K | -42.4% |
| Q3 FY2025 | Sep 30, 2025 | $412.64K | -61.3% |
| Q2 FY2025 | Jun 30, 2025 | $496.20K | -19.2% |
| Q1 FY2025 | Mar 31, 2025 | $314.40K | -58.8% |
| Q4 FY2024 | Dec 31, 2024 | $861.44K | +122.5% |
| Q3 FY2024 | Sep 30, 2024 | $1.07M | +5.1% |
| Q2 FY2024 | Jun 30, 2024 | $614.46K | – |
| Q1 FY2024 | Mar 31, 2024 | $762.28K | +180.7% |
| Q4 FY2023 | Dec 31, 2023 | $387.12K | -56.2% |
| Q3 FY2023 | Sep 30, 2023 | $1.02M | +42.0% |
| Q2 FY2023 | Jun 30, 2023 | -$101.02K | – |
| Q1 FY2023 | Mar 31, 2023 | $271.61K | – |
| Q4 FY2022 | Dec 31, 2022 | $884.76K | – |
| Q3 FY2022 | Sep 30, 2022 | $714.97K | – |
See a number that looks wrong?